77,40 <%= Resources.Global.txtDown %>
Opdateret 17:40:00
Ændring % -0,39% Fald i aktiekurs
Ændring -0,30 Fald i aktiekurs
Volume 464.958
Høj 78,74
Lav 76,98
Åben 78,00
ISIN BE0003739530
Seneste luk 77,70
# af aktier 194,51M
Markedsværdi 15.055M EUR
I dag

Market closed
UCB
Markedet er lukket, åbner klokken 09:00
 
Kursudvikling Seneste 1 uge 1 måned 3 mdr 6 mdr 1 år
 
  77,40 1,1% Stigning i aktiekurs 4,3% Stigning i aktiekurs 1,9% Stigning i aktiekurs 9,0% Stigning i aktiekurs 12,0% Stigning i aktiekurs
Powered by TradingView

Firmaprofil

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's newer drugs include Cimzia (rheumatoid arthritis, psoriatic arthritis, and Crohn's disease), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), and Briviact (epilepsy).

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
17. januar 2019 20:58:32
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190108.3 - EUROWEB6 - 2019-01-17 20:58:32 - 2019-01-17 20:58:32 - 1 - Website: OKAY